Bivalirudin in stable angina and acute coronary syndromes

Pharmacology and Therapeutics

Volumn 152, Issue , 2015, Pages 1-10

  Mavrakanas, Thomas A ^a,b   Chatzizisis, Yiannis S ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute coronary syndrome; Angina; Bivalirudin; Heparin; Non ST elevation myocardial infarction; ST elevation myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; AMIODARONE; AMPHOTERICIN B; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CHLORPROMAZINE; CLOPIDOGREL; DESULFATOHIRUDIN; DIAZEPAM; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; PROCHLORPERAZINE EDISYLATE; RETEPLASE; STREPTOKINASE; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICAGRELOR; TICLOPIDINE; VANCOMYCIN; FIBRINOLYTIC AGENT; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DISEASE REGISTRY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; MULTICENTER STUDY (TOPIC); NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; ANGINA, STABLE; ANIMAL; PROCEDURES;

ACUTE CORONARY SYNDROME; ANGINA, STABLE; ANIMALS; FIBRINOLYTIC AGENTS; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 84933679982     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.04.003     Document Type: Review

References (49)

1. D. Alexopoulos, I. Xanthopoulou, S. Deftereos, G. Sitafidis, I. Kanakakis, and M. Hamilos Bivalirudin use and one-month outcome in the context of contemporary antiplatelet treatment: insights from the Greek Antiplatelet Registry Cardiovasc Ther 32 2014 120 126
2. Authors/Task Force members, S. Windecker, P. Kolh, F. Alfonso, J.P. Collet, and J. Cremer ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 35 2014 2541 2619
3. S. Bangalore, D.J. Cohen, N.S. Kleiman, T. Regev-Beinart, S.V. Rao, and M.J. Pencina Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry Circ Cardiovasc Interv 4 2011 463 473
4. S. Bangalore, B. Toklu, A. Kotwal, A. Volodarskiy, S. Sharma, and A.J. Kirtane Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: A meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors Br Med J 349 2014 g6419
5. J.A. Bittl, J. Strony, J.A. Brinker, W.H. Ahmed, C.R. Meckel, and B.R. Chaitman Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators N Engl J Med 333 1995 764 769
6. M.A. Cavender, and M.S. Sabatine Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials Lancet 384 2014 599 606
7. M.P. Curran Bivalirudin: in patients with ST-segment elevation myocardial infarction Drugs 70 2010 909 918
8. G.D. Dangas, R. Mehran, E. Nikolsky, B.E. Claessen, A.J. Lansky, and B.R. Brodie Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: The HORIZONS-SWITCH analysis J Am Coll Cardiol 57 2011 2309 2316
9. I. Fox, A. Dawson, P. Loynds, J. Eisner, K. Findlen, and E. Levin Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans Thromb Haemost 69 1993 157 163
10. C.M. Gibson, D.A. Morrow, S.A. Murphy, T.M. Palabrica, L.K. Jennings, and P.H. Stone A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: The PROTECT-TIMI-30 trial J Am Coll Cardiol 47 2006 2364 2373
11. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, and H. Bueno ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
12. M. Hamon, C.A. Nienaber, S. Galli, K. Huber, J. Lipiecki, and J.M. Hill Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry Int J Cardiol 173 2014 290 294
13. Y. Han, J. Guo, Y. Zheng, H. Zang, X. Su, and Y. Wang Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction. The BRIGHT randomized clinical trial JAMA 2015 10.1001/jama.2015.2323
14. B. Hibbert, A. MacDougall, M. Labinaz, E.R. O'Brien, D.Y. So, and A. Dick Bivalirudin for primary percutaneous coronary interventions: Outcome assessment in the Ottawa STEMI registry Circ Cardiovasc Interv 5 2012 805 812
15. R.J. Kandrotas Heparin pharmacokinetics and pharmacodynamics Clin Pharmacokinet 22 1992 359 374
16. A. Kastrati, F.J. Neumann, J. Mehilli, R.A. Byrne, R. Iijima, and H.J. Büttner Bivalirudin versus unfractionated heparin during percutaneous coronary intervention N Engl J Med 359 2008 688 696
17. A. Kastrati, F.J. Neumann, S. Schulz, S. Massberg, R.A. Byrne, and M. Ferenc Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction N Engl J Med 365 2011 1980 1989
18. A. Koster, D. Chew, M. Gründel, H. Hausmann, O. Grauhan, and H. Kuppe An assessment of different filter systems for extracorporeal elimination of bivalirudin: An in vitro study Anesth Analg 96 2003 1316 1319
19. A.J. Leger, S.L. Jacques, J. Badar, N.C. Kaneider, C.K. Derian, and P. Andrade-Gordon Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis Circulation 113 2006 1244 1254
20. A.M. Lincoff, J.A. Bittl, R.A. Harrington, F. Feit, N.S. Kleiman, and J.D. Jackman Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863
21. A.M. Lincoff, J.A. Bittl, N.S. Kleiman, I.J. Sarembock, J.D. Jackman, and S. Mehta Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial) Am J Cardiol 93 2004 1092 1096
22. A.M. Lincoff, N.S. Kleiman, D.J. Kereiakes, F. Feit, J.A. Bittl, and J.D. Jackman Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial JAMA 292 2004 696 703
23. A.M. Lincoff, N.S. Kleiman, K. Kottke-Marchant, E.S. Maierson, K. Maresh, and K.E. Wolski Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET) Am Heart J 143 2002 847 853
24. R. Mehran, A.J. Lansky, B. Witzenbichler, G. Guagliumi, J.Z. Peruga, and B.R. Brodie Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial Lancet 374 2009 1149 1159
25. R. Nairooz, P. Sardar, H. Amin, R.V. Swaminathan, L.K. Kim, and S. Chatterjee Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction Am J Cardiol 114 2014 250 259
26. G. Ndrepepa, F.J. Neumann, E.N. Deliargyris, R. Mehran, J. Mehilli, and M. Ferenc Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: Pooled analysis from the ACUITY and ISAR-REACT 4 trials Circ Cardiovasc Interv 5 2012 705 712
27. G. Patti, V. Pasceri, L. D'Antonio, A. D'Ambrosio, M. Macrì, and G. Dicuonzo Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study) Am J Cardiol 110 2012 478 484
28. M.D. Reed, and D. Bell Clinical pharmacology of bivalirudin Pharmacotherapy 22 2002 105S 111S
29. S. Schulz, A. Kastrati, M. Ferenc, S. Massberg, K.A. Birkmeier, and K.L. Laugwitz One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: Updated results from the ISAR-REACT 4 trial EuroIntervention 9 2013 430 436
30. S. Schulz, G. Richardt, K.L. Laugwitz, T. Morath, J. Neudecker, and P. Hoppmann Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction Eur Heart J 35 2014 2285 2294
31. P.W. Serruys, P. Vranckx, and K. Allikmets Clinical development of bivalirudin (Angiox): Rationale for thrombin-specific anticoagulation in percutaneous coronary intervention and acute coronary syndromes Int J Clin Pract 60 2006 344 350
32. A. Shahzad, I. Kemp, C. Mars, K. Wilson, C. Roome, and R. Cooper Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): An open-label, single centre, randomised controlled trial Lancet 384 2014 1849 1858
33. P.G. Steg, A. van 't Hof, C.W. Hamm, P. Clemmensen, F. Lapostolle, and P. Coste Bivalirudin started during emergency transport for primary PCI N Engl J Med 369 2013 2207 2217
34. G.W. Stone, T. Clayton, E.N. Deliargyris, J. Prats, R. Mehran, and S.J. Pocock Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) J Am Coll Cardiol 63 2014 15 20
35. G.W. Stone, B.T. McLaurin, D.A. Cox, M.E. Bertrand, A.M. Lincoff, and J.W. Moses Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216
36. G.W. Stone, R. Mehran, P. Goldstein, B. Witzenbichler, A. van't Hof, and G. Guagliumi Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention. Pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials J Am Coll Cardiol 65 2015 27 38
37. G.W. Stone, J.H. Ware, M.E. Bertrand, A.M. Lincoff, J.W. Moses, and E.M. Ohman Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: One-year results from the ACUITY trial JAMA 298 2007 2497 2506
38. G.W. Stone, H.D. White, E.M. Ohman, M.E. Bertrand, A.M. Lincoff, and B.T. McLaurin Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial Lancet 369 2007 907 919
39. G.W. Stone, B. Witzenbichler, G. Guagliumi, J.Z. Peruga, B.R. Brodie, and D. Dudek Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
40. G.W. Stone, B. Witzenbichler, G. Guagliumi, J.Z. Peruga, B.R. Brodie, and D. Dudek Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): Final 3-year results from a multicentre, randomised controlled trial Lancet 377 2011 2193 2204
41. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), P.G. Steg, S.K. James, D. Atar, L.P. Badano, and C. Blömstrom-Lundqvist ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
42. D. Tavano, G. Visconti, D. D'Andrea, A. Focaccio, B. Golia, and M. Librera Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention Am J Cardiol 104 2009 1222 1228
43. The Medicines Company Summary of product characteristics: Angiox (bivalirudin) 2009 The Medicines Company Oxfordshire
44. K. Thygesen, J.S. Alpert, A.S. Jaffe, M.L. Simoons, B.R. Chaitman, and H.D. White Third universal definition of myocardial infarction Eur Heart J 33 2012 2551 2567
45. M. Valgimigli, P. Calabrò, B. Cortese, E. Frigoli, S. Garducci, and P. Rubartelli Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial J Cardiovasc Transl Res 7 2014 101 111
46. R. Waksman, O. Bertrand, M. Driesman, L. Gruberg, J. Rossi, and S. Mehta Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: Results from an international, multicenter, randomized pilot study (SWITCH III) J Interv Cardiol 26 2013 107 113
47. T.E. Warkentin, A. Greinacher, and A. Koster Bivalirudin Thromb Haemost 99 2008 830 839
48. H.D. White, D.P. Chew, J.W. Hoekstra, C.D. Miller, C.V. Pollack Jr., and F. Feit Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: Results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial J Am Coll Cardiol 51 2008 1734 1741
49. J. Wöhrle, B. Brodie, B. Witzenbichler, D. Dudek, R. Kornowski, and C. Metzger Impact of bivalirudin and paclitaxel-eluting stents on outcomes in patients undergoing primary percutaneous coronary intervention of the left anterior descending artery Am J Cardiol 112 2013 753 760